In January 2007, Boehringer and Ablynx entered into research and licensing agreement to discover new therapies for Alzheimer’s disease.
The nanobody, developed under the collaboration, triggered a €1m milestone payment to Ablynx.
Ablynx CEO and chairman Edwin Moses said, "This development candidate has the potential to be a first-in- class therapy for Alzheimer’s disease and demonstrates the power of our Nanobody platform."
The areement has a potential value of $265m in upfront and milestone payments plus undisclosed royalties on product sales.